AptarGroup publishes investor presentation on drug and consumer product dosing and dispensing technologies

AptarGroup, Inc.

AptarGroup, Inc.

ATR

0.00
  • Aptar outlined FY 2025 sales of $3.8 billion, with Pharma at 46% of revenue, Beauty 35%, Closures 19%.
  • Pharma posted $1.7 billion net sales, 6% reported growth, $608 million adjusted EBITDA, 35% adjusted EBITDA margin.
  • Beauty recorded $1.3 billion revenue, 2% core sales growth, 12.1% adjusted EBITDA margin, 18% of total adjusted EBITDA.
  • Capital deployment over 2017-2025: $3.5 billion to CapEx and acquisitions, $0.9 billion dividends, $0.9 billion repurchases.
  • Balance sheet target of 1-3x leverage long term, with R&D spending at about 3% of sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief on June 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.